Latest from Solve

All
News
Product
Research
Case Studies
Announcements
Engineering
Events
Company
AI for Patents
Customer Advisory Board
August 4, 2026Maiwald Chooses Solve Intelligence for Selected AI-Supported IP WorkflowsSolve Intelligence is proud to share that Maiwald, one of Germany’s largest and most progressive intellectual property firms, works with Solve Intelligence on selected AI-supported workflows in its patent and legal practice groups. Following an evaluation period during which selected functionalities were assessed for approved internal use cases, Maiwald and Solve have formed an enterprise partnership for 2026. The rollout reflects the same careful approach Maiwald brings to its client work. Solve enables customers in Europe to process data on servers located within Europe and holds recognized information-security certifications. In addition, Solve offers contractual commitments designed to protect confidential professional information in line with applicable statutory confidentiality obligations and professional conduct requirements. Against that background, any use of AI-supported tools took place only within approved governance structures and under applicable professional, contractual, confidentiality and data-protection requirements. That balance of innovation and professional judgment is characteristic of Maiwald. The firm has spent decades setting a standard for IP work in Europe: rigorous prosecution, a formidable contentious practice, and interdisciplinary teams of patent attorneys and attorneys-at-law working side by side. The firm approached AI the same way, methodically, with a clear sense of where it adds leverage and where an experienced attorney’s judgment remains irreplaceable.Read article
MORE STORIES
May 28, 2026AI X IP Thought Leader Exchange with Solve Intelligence, Haynes Boone, and 100+ Leading Voices in IPSolve Intelligence partnered with AmLaw 100 firm Haynes Boone to bring together 100+ senior IP leaders in Silicon Valley for a candid discussion on how AI is being used in patent practice today, and how that's shifting over the next 12 months. The evening was led by Leah Poynter Waterland (Sr. Director, Cisco), Jeff Draeger (Chief Patent Counsel, Intel), David McCombs (Partner and Board Member, Haynes Boone), Tony Capecci (Director of Practice Innovation, Haynes Boone), and Mallun Yen (Founder, Operator Collective; IP leader and Ex-Cisco). The room was 70% in-house, drawing Heads of IP and senior IP leaders from across enterprise software and cloud (Microsoft, IBM, Snowflake), semiconductors (Intel, Applied Materials), life sciences (Johnson & Johnson, Pfizer, Gilead), mobility and autonomy (Tesla, Waymo), connected devices and networks (Cisco, Samsung Research America), and AI labs (Mistral AI). The remaining 30% were outside counsel from firms including BCLP, Finnegan, Perkins Coie, Procopio, and Skadden. Key Insights Today, Solve supports global IP teams deploying AI agents for large-scale tasks including search across millions of patent and non-patent literature, portfolio analysis on thousands of assets, and claim charting, focussed on transparent source-backed and auditable outputs. Every IP leader in the room had either rolled out an AI patent platform or was in active procurement. Successful AI implementation requires collaboration and trusted long-term partnerships between IP teams, vendors, and outside counsel. Solve CEO Chris Parsonson expects per-user token usage to grow more than 1000x over the next 12 months.Read article
May 14, 2026Teva v. Eli Lilly: The Four Drafting Choices That Won $176.5MThe Federal Circuit Panel's April 16, 2026 decision in Teva v. Eli Lilly reinstates a $176.5M verdict and draws a clear distinction under §112 between method-of-treatment and composition claims. The decision highlights the importance of drafting choices, like those made by Teva 2006. Teva shows how much §112 outcomes turn on drafting choices rather than the volume of disclosure. From a specification describing a single humanized antibody, the patentee framed the invention as a method of treatment, anchored the genus to a known biological target, and relied on humanization as routine art within the POSA's knowledge. These are structural choices, made years before litigation, that shape how a patent reads in enforcement decades later. These choices are exactly what purpose-built tools like Solve Intelligence are designed to surface early on, during drafting, when they can be considered consciously and proactively. The alternative may be that issues only become apparent during litigation, when it is often too late to change a decision that was made previously, whether intentionally or not. Key takeaways Teva v. Eli Lilly (Fed. Cir. Apr. 16, 2026) marks the first clear limit on Amgen v. Sanofi. Amgen's §112 calculus does not extend to method-of-treatment claims reciting an antibody genus. Same specification, same genus, yet the antibody claims failed in IPR while the headache claims won at trial. One humanized antibody, a known biological target, and routine humanization techniques were enough to satisfy §112. Four drafting choices won the case: claim category, functional anchoring, routine art, one embodiment. Teva is a re-opening event for life sciences portfolios with genus claims.Read article
April 3, 2026How Solve Intelligence Handles Invention Disclosures and Unstructured DataIf you've been drafting patents for any length of time, you know the real bottleneck is often not the drafting itself. It's the messy inputs that precede it: partial forms, internal review decks, or email threads where the inventive aspects are buried. Getting from that to a coherent starting point for a draft consumes time most practices simply can't afford. AI can perform much of that translation work: extracting what matters, flagging what's missing, and generating the necessary follow-up questions based on holes and shortcomings. But it must operate inside proper confidentiality controls, and its output requires attorney review before going near a draft. This guide covers how that works in practice in Solve Intelligence's platform . Key takeaways The disclosure bottleneck is upstream; AI structures messy inputs before the drafting phase begins. AI extracts features, normalises terminology, surfaces gaps, and generates inventor questions, but attorney review is mandatory. The danger is plausible but fabricated detail, not obvious errors. Watch for AI-generated parameters or 'helpful' specifics. Disclosures contain trade secrets and unpublished IP. Use only tools with verified zero-training, zero-retention policies and enterprise-grade security. A sensible pilot, without client approval, uses anonymised or historical disclosures to define 'good' output and track key metrics over limited timeframe.Read article
Customers

Customers report 50%+ efficiency and quality improvements.

“Solve are so far above what other people are doing. That’s why we decided to go with Solve.”Larissa BifanoPartner, DLA Piper
“Solve Intelligence stands out for their genuine customer obsession, particularly in how they partner with users to co-create tailored templates.”Jeff DraegerChief Patent Counsel, Intel
“After extensively evaluating many products, we concluded that Solve Intelligence best met the needs of our attorneys and our clients.”Laura C. BrutmanShareholder, Banner Witcoff
“We see Solve Intelligence as the key to our success in the future.”Thomas YeePartner, Ashurst Perkins Coie
“We are using the AI to help us produce a better work product within the constraints, whether it’s a fixed fee or a loosely defined budgetary constraint. The AI allows us to provide that better work product.”George ChenPartner & Global Board Member, BCLP
“Solve is providing the ability to give a robust analysis to clear products, in a way that allows me to give security to the client, and also allows me to do my job a lot better.”Nicholas SchmidbauerPartner, Quarles
“By understanding lawyers, not just technology, Solve is truly innovating on what the practice of law looks like.”Joshua DavenportShareholder, Banner Witcoff
Cookie settingsBy clicking “Accept all”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. For further details see our
Privacy Policy
Manage cookie preferencesChoose which cookies we may store on your device. Essentials keep the site working and cannot be turned off.EssentialsNecessary for the site to function. Always on.Always activeAnalyticsMeasures usage and improves your experience.MarketingUsed for targeted advertising.Cookie preferences